US2013190839A1PendingUtilityA1

Drug delivery using a sacrificial host

44
Assignee: RAPSEY JANEPriority: Jan 20, 2012Filed: Jan 20, 2012Published: Jul 25, 2013
Est. expiryJan 20, 2032(~5.5 yrs left)· nominal 20-yr term from priority
Inventors:Jane RapseyMartin SvehlaPeter SchullerChristopher Robert Miller
A61L 27/18A61P 39/06A61P 31/00A61P 29/00A61L 27/54A61F 2250/0067A61L 2300/602A61N 1/0541A61L 2430/14A61L 27/58A61F 11/00A61L 27/20
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An implantable drug-doped component, e.g., a cochlear implant, includes host material, a host-embedded drug and a sacrificial material integrated with the host. Upon exposure of the sacrificial material to a solvent, e.g., perilymph fluid, voids in the host are created which facilitate release of the drug. The host can be, e.g., polysiloxane or silicone rubber. The sacrificial material, e.g., can be a glucose monomer, sugar, cyclodextrin, a salt, a bioresorbable material, hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, polyacrylic acid, etc. Alternatively, the sacrificial material can be the host, and can facilitate release of the drug through changing a property of the sacrificial material, e.g., by exposing the component to an ethanol wash. For a cochlear implant, e.g., the drug doped material can be applied to a non-stimulating surface of the electrode array.

Claims

exact text as granted — not AI-modified
1 . An implantable drug-doped component comprising:
 a host material,   a drug embedded in the host material, and   a sacrificial material integrated with the host material;   wherein the sacrificial material facilitates the release of the embedded drug from the drug-doped component.   
     
     
         2 . The implantable drug-doped component of  claim 1  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through the creation of voids in the host material upon dissolution of the sacrificial material upon contact with a solvent. 
 
     
     
         3 . The implantable drug-doped component of  claim 2  wherein:
 the solvent is perilymph fluid. 
 
     
     
         4 . The implantable drug-doped component of  claim 2  wherein:
 the contact with a solvent is at least one of: during surgery, and upon implant of the component in a recipient. 
 
     
     
         5 . The implantable drug-doped component of  claim 2  wherein:
 the host material is a polysiloxane. 
 
     
     
         6 . The implantable drug-doped component of  claim 2  wherein:
 the host material is a silicone rubber. 
 
     
     
         7 . The implantable drug-doped component of  claim 2  wherein:
 the drug at least one material from the group comprising: an anti-inflammatory, a growth factor, an antibody, an anti-oxidant, an antibiotic, and a corticosteroid. 
 
     
     
         8 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is at least one of: a glucose monomer, a sugar. 
 
     
     
         9 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a cyclodextrin. 
 
     
     
         10 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a material that is at least one of dissolvable and re-sorbable in the environment of an implant site. 
 
     
     
         11 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a salt. 
 
     
     
         12 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a bioresorbable material. 
 
     
     
         13 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is at least one material from the group comprising: hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, and polyacrylic acid. 
 
     
     
         14 . The implantable drug-doped component of  claim 1  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through changing a property of the sacrificial material. 
 
     
     
         15 . The implantable drug-doped component of  claim 14  wherein:
 the change in property has been brought about by exposing the drug-doped component to an ethanol wash. 
 
     
     
         16 . A cochlear implant comprising:
 an electrode array comprising a most basal electrode contact; and   a drug-doped component comprising:
 a host material, 
 a drug embedded in the host material, and 
 a sacrificial material integrated with the host material; 
 wherein the sacrificial material facilitates the release of the embedded drug from the drug-doped component. 
   
     
     
         17 . The cochlear implant of  claim 16  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through the creation of voids in the host material upon dissolution of the sacrificial material upon contact with a solvent. 
 
     
     
         18 . The cochlear implant of  claim 17  wherein:
 the solvent is perilymph fluid. 
 
     
     
         19 . The cochlear implant of  claim 17  wherein:
 the contact with a solvent is at least one of: during surgery, and upon implant of the component in a recipient. 
 
     
     
         20 . The cochlear implant of  claim 17  wherein:
 the host material is a polysiloxane. 
 
     
     
         21 . The cochlear implant of  claim 17  wherein:
 the host material is a silicone rubber. 
 
     
     
         22 . The cochlear implant of  claim 17  wherein:
 the drug at least one material from the group comprising: an anti-inflammatory, a growth factor, an antibody, an anti-oxidant, an antibiotic, and a corticosteroid. 
 
     
     
         23 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is at least one of: a glucose monomer, a sugar. 
 
     
     
         24 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a cyclodextrin. 
 
     
     
         25 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a material that is at least one of dissolvable and re-sorbable in the environment of an implant site. 
 
     
     
         26 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a salt. 
 
     
     
         27 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a bioresorbable material. 
 
     
     
         28 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is at least one material from the group comprising: hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, and polyacrylic acid. 
 
     
     
         29 . The cochlear implant of  claim 17  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through changing a property of the sacrificial material. 
 
     
     
         30 . The cochlear implant of  claim 29  wherein:
 the change in property has been brought about by exposing the drug-doped component to an ethanol wash. 
 
     
     
         31 . The cochlear implant of  claim 17  wherein:
 the drug doped material is applied to a non-stimulating surface of the electrode array. 
 
     
     
         32 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is a physical feature of the stimulating medical device. 
 
     
     
         33 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is one physical feature from the group of physical features comprising: a soft tip, a ridge, and a spine. 
 
     
     
         34 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is not applied on the basal side of the most basal electrode contact.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.